Significant Discrepancies in Cancer Treatment For HIV-Infected Patients

This article originally appeared here.
Researchers are unsure what's driving the difference in care
Researchers are unsure what's driving the difference in care

HealthDay News — While powerful HIV medications are allowing patients to live longer, these same patients are less likely to get treatment for cancer if it develops, according to a study published online May 17 in Cancer.

Gita Suneja, MD, assistant professor of radiation oncology at the University of Utah School of Medicine, and colleagues examined a database of people diagnosed with cancer in the United States between 2003 and 2011. The study included 2.2 million cancer patients who did not have HIV and 10,265 cancer patients who were infected with HIV. All participants were younger than 65. Overall, HIV-infected patients were younger (with a median age of 47, compared to 55), more likely to be male (77 versus 48%), and much more likely to be black (41 versus 13%).

The HIV-infected patients were more likely to suffer from anal cancer and Hodgkin's lymphoma and much less likely to have breast and prostate cancer. More than 40% of the HIV-infected patients had diffuse large B-cell lymphoma; just 2% of the other patients did. The differences persisted even when the researchers adjusted their statistics so they wouldn't be influenced by high or low numbers of people who shared certain factors such as race, gender, and age.

"We found large differences in cancer treatment rates," Suneja told HealthDay. "For most cancers, HIV-infected patients were two to three times more likely to receive no cancer treatment compared to uninfected people."

Abstract
Full Text (subscription or payment may be required)

Loading links....